Mukherjee Swati, Dowd Kimberly A, Manhart Carolyn J, Ledgerwood Julie E, Durbin Anna P, Whitehead Stephen S, Pierson Theodore C
Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
J Virol. 2014 Jul;88(13):7210-20. doi: 10.1128/JVI.03690-13. Epub 2014 Apr 16.
The production of neutralizing antibodies (NAbs) is a correlate of protection for many human vaccines, including currently licensed vaccines against flaviviruses. NAbs are typically measured using a plaque reduction neutralization test (PRNT). Despite its extensive use, parameters that impact the performance of the PRNT have not been investigated from a mechanistic perspective. The results of a recent phase IIb clinical trial of a tetravalent dengue virus (DENV) vaccine suggest that NAbs, as measured using a PRNT performed with Vero cells, do not correlate with protection. This surprising finding highlights the importance of understanding how well the PRNT captures the complexity of the NAb response to DENV. In this study, we demonstrated that the structural heterogeneity of flaviviruses arising from inefficient virion maturation impacts the results of neutralization assays in a cell type-dependent manner. Neutralization titers of several monoclonal antibodies were significantly reduced when assayed on Vero cells compared to Raji cells expressing DC-SIGNR. This pattern can be explained by differences in the efficiency with which partially mature flaviviruses attach to each cell type, rather than a differential capacity of antibody to block infection. Vero cells are poorly permissive to the fraction of virions that are most sensitive to neutralization. Analysis of sera from recipients of live-attenuated monovalent DENV vaccine candidates revealed a strong correlation between the sensitivity of serum antibodies to the maturation state of DENV and cell type-dependent patterns of neutralization. Cross-reactive patterns of neutralization may be underrepresented by the "gold-standard" PRNT that employs Vero cells.
Cell type-dependent patterns of neutralization describe a differential capacity of antibodies to inhibit virus infection when assayed on multiple cellular substrates. In this study, we established a link between antibodies that neutralize infection in a cell type-dependent fashion and those sensitive to the maturation state of the flavivirus virion. We demonstrated that cell type-dependent neutralization reflects a differential capacity to measure neutralization of viruses that are incompletely mature. Partially mature virions that most efficiently bind maturation state-sensitive antibodies are poorly represented by assays typically used in support of flavivirus vaccine development. The selection of cellular substrate for neutralization assays may significantly impact evaluation of the neutralization potency of the polyclonal response. These data suggest that current assays do not adequately capture the full complexity of the neutralizing antibody response and may hinder the identification of correlates of protection following flavivirus vaccination.
产生中和抗体(NAbs)是许多人类疫苗(包括目前已获许可的抗黄病毒疫苗)提供保护作用的一个相关指标。中和抗体通常采用蚀斑减少中和试验(PRNT)进行检测。尽管该试验应用广泛,但尚未从机制角度对影响PRNT性能的参数进行研究。一项近期关于四价登革热病毒(DENV)疫苗的IIb期临床试验结果表明,用Vero细胞进行PRNT检测时所测得的中和抗体与保护作用不相关。这一惊人发现凸显了了解PRNT能多好地反映中和抗体对登革热病毒反应复杂性的重要性。在本研究中,我们证明了由于病毒粒子成熟效率低下导致的黄病毒结构异质性以细胞类型依赖的方式影响中和试验结果。与表达DC - SIGNR的Raji细胞相比,在Vero细胞上检测时,几种单克隆抗体的中和效价显著降低。这种模式可以通过部分成熟的黄病毒附着于每种细胞类型的效率差异来解释,而不是抗体阻断感染的能力差异。Vero细胞对最易被中和的病毒粒子部分的允许性较差。对减毒活单价登革热病毒候选疫苗接种者血清进行分析发现,血清抗体对登革热病毒成熟状态的敏感性与细胞类型依赖的中和模式之间存在很强的相关性。采用Vero细胞的“金标准”PRNT可能无法充分体现交叉反应性中和模式。
细胞类型依赖的中和模式描述了在多种细胞底物上检测时抗体抑制病毒感染的不同能力。在本研究中,我们建立了以细胞类型依赖方式中和感染的抗体与对黄病毒粒子成熟状态敏感的抗体之间的联系。我们证明细胞类型依赖的中和反映了检测不完全成熟病毒中和作用的不同能力。通常用于支持黄病毒疫苗研发的检测方法不能很好地体现最有效地结合成熟状态敏感抗体的部分成熟病毒粒子。用于中和试验的细胞底物选择可能会显著影响对多克隆反应中和效力的评估。这些数据表明,目前的检测方法不能充分反映中和抗体反应的全部复杂性,可能会阻碍黄病毒疫苗接种后保护相关指标的确定。